Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Agilent, Yourgene, Combinati, More

Agilent SureSelect XT HS2 RNA Reagent Kit 

Agilent has launched its SureSelect XT HS2 RNA Reagent Kit. The kit offers a modular design that provides a simple and parallel approach for both RNA and DNA samples, which the firm noted will help customers streamline and combine workflows without losing time optimizing different kits for different sample types.

Agilent's kit will allow customers to accurately profile gene expression and detect RNA fusions using low-input formalin-fixed paraffin-embedded samples. The kit supports 384 unique dual sample indexes and helps customers to multiplex hundreds of samples in a single sequencing run without worrying about index hopping, the firm said. The kit also features molecular barcodes for more efficient de-duplication of sequencing reads and more accurate gene expression analysis.


Yourgene Iona Nx Noninvasive Prenatal Test 

Yourgene this week launched the Iona Nx Noninvasive Prenatal Test (NIPT) after having received CE marking for it in June. Iona Nx is designed to run on Illumina’s NextSeq 550 Dx next-generation sequencing platform, and uses the Yourgene SP150 and Yourgene QS250 instruments to combine DNA extraction, sample preparation, and enrichment ahead of the sequencing step.

The QS250 is powered by Ranger technology from Coastal Genomics, which Yourgene acquired recently acquired, and features a step that enriches fetal fraction two-fold, reducing the amount of sequencing necessary and decreasing cost. The assay has greater than 99.99 percent accuracy, according to the company, and features whole-genome analysis including for trisomy 21, 18, and 13; sex chromosomal aneuploidies; other autosomal aneuploidies; and optional fetal sex determination. It will also feature microdeletions analysis in the future, the company said.

Yourgene will initially transition existing customers to the new assay in the UK and France, followed by other European territories.


Combinati Q SARS-CoV-2 Triple Assay for Absolute Q Digital PCR System

Combinati has launched the Q SARS-CoV-2 Triplex Assay for its Absolute Q digital PCR system. The multiplexed, research-use-only assay detects SARS-CoV-2 nucleic acids from extracted samples in a single reaction. The workflow includes microfluidic array partitioning plates and required reagents, has one hands-on step, and provides results in 90 minutes. The assay demonstrates sensitivity down to single viral targets, enabling researchers to detect trace amounts of virus even in a high background of human genomic DNA, according to the company.


For more new products and services, please visit the New Products page on our website. 

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.